Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jun;75(2):382-384.
doi: 10.1111/biom.12993. Epub 2019 Apr 3.

Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall

Eric S Leifer  1 , Nancy L Geller  1
Affiliations
Comment

Discussion of "A Hybrid Phase I-II/III Clinical Trial Design Allowing Dose Re-Optimization in Phase III" by Andrew G. Chapple and Peter F. Thall

Eric S Leifer et al. Biometrics. 2019 Jun.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Ghosh, P., Liu, L., Senchaudhuri, P., Gao, P., Mehta, C. (2017). Design and monitoring of multi-arm multi-stage clinical trials. Biometrics 73, 1289-1299.
    1. Korn, E. L., Freidlin, B., Abrams, J. S., Halabi, S. (2012). Design issues in randomized phase II/III trials. J Clin Oncol 30, 667-671.
    1. Royston, P., Barthel, F. M. S., Parmar, M. K. B., Choodari- Oskooei, B., Isham, V. (2011). Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials 12, 81.
    1. Thall, P. F., Cook, J. D. (2004). Dose-finding based on efficacy-toxicity trade-offs. Biometrics 60, 684-693.
    1. Thall, P. F., Cook, J. D., Estey, E. H. (2006). Adaptive dose selection using efficacy-toxicity trade-offs: Illustrations and practical considerations. J Biopharm Stat 16, 623-638.

MeSH terms

LinkOut - more resources